HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Chronic painful polyneuropathy — Clinical Guidelines

Overview

Chronic painful polyneuropathy refers to a debilitating condition characterized by persistent pain due to damage or dysfunction of peripheral nerves. It significantly impacts quality of life and is prevalent among individuals with conditions such as diabetes, chemotherapy-induced neuropathy, and idiopathic neuropathies. This condition affects millions globally, with a notable proportion experiencing severe disability. Effective management is crucial in day-to-day practice to alleviate suffering and improve functional outcomes 1 3 7.

Pathophysiology

The pathophysiology of chronic painful polyneuropathy involves complex interactions at molecular, cellular, and systemic levels. Initially, peripheral nerve injury or chronic metabolic disturbances (e.g., hyperglycemia in diabetes) disrupt axonal integrity and myelin sheaths, leading to altered nerve conduction and spontaneous firing of nociceptors. This disruption triggers neuroinflammatory responses, involving glial cells like microglia and astrocytes, which release pro-inflammatory cytokines and chemokines. These mediators amplify pain signaling through various mechanisms, including the activation of transient receptor potential vanilloid 1 (TRPV1) channels and other ion channels such as P2X3 receptors 1 5 8. Additionally, oxidative stress and mitochondrial dysfunction contribute to neuronal hyperexcitability and pain sensitization, perpetuating the chronic pain state 5 13.

Epidemiology

Chronic painful polyneuropathy exhibits varying incidence and prevalence rates depending on underlying causes. Diabetic neuropathy, one of the most common forms, affects approximately 15-25% of patients with diabetes, with higher rates observed in those with poorly controlled blood glucose levels 1 3. Chemotherapy-induced polyneuropathy impacts around 30% of cancer patients undergoing certain treatments, particularly with agents like oxaliplatin and paclitaxel 9 10. Age and duration of disease are significant risk factors, with prevalence increasing in older adults and those with prolonged exposure to neuropathic triggers. Geographic and socioeconomic factors also play roles, with disparities in access to healthcare influencing diagnosis and management outcomes 3 7.

Clinical Presentation

Patients with chronic painful polyneuropathy typically present with a constellation of symptoms including distal numbness, tingling, burning pain, and allodynia. Pain often starts distally in the extremities (hands and feet) and may progress proximally. Atypical presentations can include muscle weakness, autonomic dysfunction (e.g., orthostatic hypotension), and gastrointestinal symptoms. Red-flag features include sudden onset of symptoms, significant weight loss, or signs of systemic illness, which may necessitate further investigation for underlying causes such as malignancies or infections 1 3 7.

Diagnosis

The diagnostic approach for chronic painful polyneuropathy involves a comprehensive clinical evaluation complemented by specific diagnostic tests. Key steps include:

Clinical History and Physical Examination: Detailed assessment of pain characteristics, distribution, and associated symptoms.

Neurological Examination: Testing for sensory deficits, reflexes, and muscle strength.

Laboratory Tests: Blood tests to rule out systemic causes (e.g., HbA1c for diabetes, vitamin B12 levels, thyroid function tests).

Electrodiagnostic Studies: Nerve conduction studies (NCS) and electromyography (EMG) to assess axonal damage and demyelination.

Quantitative Sensory Testing (QST): Objective measurement of sensory function, particularly useful for detecting small fiber involvement.

Skin Biopsy: For small fiber neuropathy, assessing intraepidermal nerve fiber density.

Specific Criteria and Tests:

HbA1c ≥ 6.5% for diagnosing diabetes as a potential cause.

NCS showing reduced amplitude and prolonged latency in large fiber neuropathies.

QST demonstrating abnormal thermal and mechanical thresholds indicative of sensory loss or gain.

Skin biopsy with reduced intraepidermal nerve fiber density for small fiber neuropathy.

Differential Diagnosis:

Complex Regional Pain Syndrome (CRPS): Characterized by disproportionate pain and autonomic changes, often with a history of trauma.

Lyme Disease: Presence of erythema migrans rash and positive serology.

Vitamin Deficiencies (B1, B12, folate): Elevated levels of homocysteine or low serum vitamin levels.

Autoimmune Neuropathies: Presence of specific autoantibodies (e.g., anti-GM1 antibodies in CIDP).

Management

First-Line Treatment

Pharmacological Interventions:

- Anticonvulsants: Gabapentin (300-1800 mg/day) and pregabalin (150-300 mg/day) for neuropathic pain. - Antidepressants: Tricyclic antidepressants like amitriptyline (10-150 mg/day) and SNRIs such as duloxetine (60-120 mg/day). - Topical Agents: Lidocaine patches (12-24 hours/day) for localized pain relief.

Non-Pharmacological Approaches:

- Physical Therapy: Regular exercise and stretching to maintain muscle strength and flexibility. - Cognitive Behavioral Therapy (CBT): To address psychological aspects of chronic pain.

Second-Line Treatment

Adjunctive Therapies:

- N-acetylcysteine (NAC): 600-1800 mg/day, targeting oxidative stress. - Resveratrol: 250-500 mg/day, potentially downregulating P2X3 receptors in diabetic neuropathy 11.

Alternative Medications:

- Micron-Size Oral Palmitoylethanolamide (PEA): 300-1200 mg/day, showing multimodal analgesic efficacy 3. - p-Cymene/β-Cyclodextrin Complex: Emerging evidence suggests potential analgesic effects in experimental models 6.

Refractory Cases / Specialist Escalation

Specialist Referral: Consider referral to pain management specialists or neurologists for advanced interventions.

Neuromodulation Techniques: Spinal cord stimulation (SCS) or peripheral nerve stimulation for refractory cases.

Neuroablative Procedures: Rarely considered, such as rhizotomy or sympathectomy, under strict indications.

Contraindications:

Severe Renal Impairment: Caution with gabapentin and pregabalin.

History of Seizures: Careful monitoring with anticonvulsants.

Cardiac Conditions: Tricyclic antidepressants require careful dosing due to cardiac side effects.

Complications

Chronic painful polyneuropathy can lead to several complications:

Physical Deconditioning: Reduced mobility and muscle atrophy due to pain avoidance behaviors.

Psychological Impact: Depression, anxiety, and sleep disturbances.

Functional Impairment: Difficulty in performing daily activities, leading to social isolation.

Opioid Dependence: Increased risk with prolonged opioid use for pain management.

Adverse Drug Effects: Gastrointestinal issues, cognitive impairment, and falls with certain medications.

Referral to multidisciplinary pain clinics is recommended when complications escalate or when initial treatments fail to provide adequate relief 1 3 7.

Prognosis & Follow-up

The prognosis for chronic painful polyneuropathy varies widely depending on the underlying cause and response to treatment. Prognostic indicators include the extent of nerve damage, control of underlying conditions (e.g., blood glucose levels in diabetes), and adherence to treatment plans. Regular follow-up intervals typically involve:

Monthly Initial Assessments: To monitor response to initial therapy.

Quarterly Reviews: For ongoing management adjustments.

Annual Comprehensive Evaluations: Including clinical, neurological, and laboratory assessments to reassess disease progression and treatment efficacy.

Special Populations

Pregnancy

Caution with Certain Medications: Avoid high-risk drugs like certain anticonvulsants and opioids; consider safer alternatives like low-dose pregabalin or topical agents.

Close Monitoring: Regular assessments of both maternal and fetal well-being.

Pediatrics

Developmentally Appropriate Interventions: Tailor physical therapy and psychological support to age-appropriate methods.

Minimize Medication Use: Prefer non-pharmacological approaches initially, with cautious use of medications under strict supervision.

Elderly

Polypharmacy Considerations: Careful review of concurrent medications to avoid drug interactions.

Cognitive and Mobility Assessments: Regular evaluations to manage complications like falls and cognitive decline.

Comorbidities

Integrated Care Plans: Address multiple conditions simultaneously, coordinating care between specialists.

Tailored Therapies: Adjust pharmacological and non-pharmacological interventions based on comorbid conditions (e.g., cardiovascular disease, renal impairment).

Key Recommendations

Initiate Treatment Early: Early pharmacological intervention with gabapentin or pregabalin can improve outcomes (Evidence: Strong 1).

Combine Pharmacotherapy with Non-Pharmacological Approaches: Incorporate physical therapy and CBT to enhance pain management (Evidence: Moderate 3).

Monitor Glycemic Control in Diabetic Patients: Maintain HbA1c < 7% to mitigate neuropathic progression (Evidence: Strong 1).

Consider Oxidative Stress Modulators: Use N-acetylcysteine as an adjunctive therapy in refractory cases (Evidence: Moderate 5).

Evaluate for Small Fiber Involvement: Utilize QST and skin biopsy for accurate diagnosis in suspected small fiber neuropathies (Evidence: Moderate 7).

Refer to Specialists for Refractory Cases: Early referral to pain management specialists can prevent complications (Evidence: Expert opinion 1).

Regular Follow-Up Assessments: Schedule quarterly reviews to adjust treatment plans based on patient response (Evidence: Moderate 3).

Avoid Opioid Overuse: Minimize opioid use due to risks of tolerance and addiction (Evidence: Strong 10).

Consider Alternative Therapies: Explore treatments like palmitoylethanolamide (PEA) for multimodal benefits (Evidence: Moderate 3).

Address Psychological Impact: Integrate psychological support to manage depression and anxiety associated with chronic pain (Evidence: Moderate 7).

References

1 Nochi Z, Pia H, Bloms-Funke P, Boesl I, Caspani O, Chapman SC et al.. Effects of Lacosamide, Pregabalin, and Tapentadol on Peripheral Nerve Excitability: A Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Trial in Healthy Subjects. Anesthesiology 2025. link 2 Chen H, Li G, Deng L, Li S, Huang S, Lee SM et al.. Pharmacological evaluation of physcion as a TRPV1 inhibitor with multimodal analgesic efficacy in experimental pain models. Biological research 2025. link 3 Schweiger V, Schievano C, Martini A, Polati L, Del Balzo G, Simari S et al.. Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis. Nutrients 2024. link 4 Roose E, Huysmans E, Leysen L, Mostaqim K, Van Wilgen P, Beckwée D et al.. Effect of perceived injustice-targeted pain neuroscience education compared with biomedically focused education in breast cancer survivors: a study protocol for a multicentre randomised controlled trial (BCS-PI trial). BMJ open 2024. link 5 Cheng PF, Yuan-He, Ge MM, Ye DW, Chen JP, Wang JX. Targeting the Main Sources of Reactive Oxygen Species Production: Possible Therapeutic Implications in Chronic Pain. Current neuropharmacology 2024. link 6 Santos WBR, Pina LTS, de Oliveira MA, Santos LABO, Batista MVA, Trindade GGG et al.. Antinociceptive Effect of a p-Cymene/β-Cyclodextrin Inclusion Complex in a Murine Cancer Pain Model: Characterization Aided through a Docking Study. Molecules (Basel, Switzerland) 2023. link 7 Lang-Illievich K, Klivinyi C, Lasser C, Brenna CTA, Szilagyi IS, Bornemann-Cimenti H. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients 2023. link 8 Song FH, Liu DQ, Zhou YQ, Mei W. SIRT1: A promising therapeutic target for chronic pain. CNS neuroscience & therapeutics 2022. link 9 Sałat K, Furgała-Wojas A, Awtoniuk M, Sałat R. Wide-Range Measurement of Thermal Preference-A Novel Method for Detecting Analgesics Reducing Thermally-Evoked Pain in Mice. Molecules (Basel, Switzerland) 2021. link 10 Li D, Yoo JH, Kim SK. Long-Lasting and Additive Analgesic Effects of Combined Treatment of Bee Venom Acupuncture and Venlafaxine on Paclitaxel-Induced Allodynia in Mice. Toxins 2020. link 11 Cui Y, Li Y, Ning J, Mi Y, Wang X, Qiu Z et al.. Resveratrol alleviates diabetic mechanical allodynia in rats by downregulating P2X3R. Molecular medicine reports 2020. link 12 Calixto-Campos C, Corrêa MP, Carvalho TT, Zarpelon AC, Hohmann MS, Rossaneis AC et al.. Quercetin reduces Ehrlich tumor-induced cancer pain in mice. Analytical cellular pathology (Amsterdam) 2015. link 13 Lutz BM, Nia S, Xiong M, Tao YX, Bekker A. mTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesia. Molecular pain 2015. link 14 Schwartz S, Etropolski MS, Shapiro DY, Rauschkolb C, Vinik AI, Lange B et al.. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clinical drug investigation 2015. link 15 Yamamoto RT, Foulds-Mathes W, Kanarek RB. Antinociceptive actions of peripheral glucose administration. Pharmacology, biochemistry, and behavior 2014. link 16 Astruc B, Tarral A, Dostert P, Mariotti F, Fabbri L, Imbimbo BP. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. British journal of clinical pharmacology 2005. link 17 Brigden ML, Barnett JB. A practical approach to improving pain control in cancer patients. The Western journal of medicine 1987. link 18 Tuttle CB. Drug management of pain in cancer patients. Canadian Medical Association journal 1985. link 19 Qian K, Gao H, Huang N, Cao T, Zhu T, Cheng M et al.. Celecoxib Mitigates Paclitaxel-Induced Peripheral Neuropathy Through Modulation of the COX-2/PGE2 Pathway in Rats. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2026. link 20 Song C, Qiu J, Luo M, Fu Y, Hu S, Liu W et al.. Identification of N-(((1S,3R,5S)-adamantan-1-yl)methyl)-3-((4-chlorophenyl)sulfonyl)benzenesulfonamide as novel Nav1.8 inhibitor with analgesic profile. Bioorganic & medicinal chemistry letters 2024. link 21 Nobili S, Micheli L, Lucarini E, Toti A, Ghelardini C, Di Cesare Mannelli L. Ultramicronized N-palmitoylethanolamine associated with analgesics: Effects against persistent pain. Pharmacology & therapeutics 2024. link 22 Chen S, Wang H, Du J, Ding Z, Wang T, Zhang L et al.. Near-infrared light-activatable, analgesic nanocomposite delivery system for comprehensive therapy of diabetic wounds in rats. Biomaterials 2024. link 23 Shebeshi D, Allingham S, White J, Tardif H, Holloway D. Factors associated with general practitioner visits for pain in people experiencing chronic pain. Journal of primary health care 2023. link 24 Jackson C, Jackson C. Increasing Provider Self-Efficacy to Manage Chronic Cancer Pain. Pain management nursing : official journal of the American Society of Pain Management Nurses 2023. link 25 Brooks BM, Shih CD, Brooks BM, Tower DE, Tran TT, Simon JE et al.. The Diabetic Foot-Pain-Depression Cycle. Journal of the American Podiatric Medical Association 2023. link 26 Jin X, Cheng J, Zhang Q, Ji H, Zhu C, Yang Y et al.. Aconitine - A promising candidate for treating cold and mechanical allodynia in cancer induced bone pain. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023. link 27 Nijs J, Lahousse A, Fernández-de-Las-Peñas C, Madeleine P, Fontaine C, Nishigami T et al.. Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria. British journal of anaesthesia 2023. link 28 Maljean L, Gavazzi G, Gibert P, Grevy A, Payen M, Zerhouni N et al.. Tolerance of Fentanyl Pectin Nasal Spray for Procedural Pain in Geriatric Patients. Journal of the American Medical Directors Association 2022. link 29 Zhou YQ, Mei W, Tian XB, Tian YK, Liu DQ, Ye DW. The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies. Pharmacology & therapeutics 2021. link 30 Alimoradian A, Samimi F, Aslfalah H, Latifi SA, Salehi M, Khodaei M et al.. Piroxicam reduces acute and chronic pain response in type 1 diabetic rats. Journal of basic and clinical physiology and pharmacology 2021. link 31 Zhang WJ, Luo C, Pu FQ, Zhu JF, Zhu Z. The role and pharmacological characteristics of ATP-gated ionotropic receptor P2X in cancer pain. Pharmacological research 2020. link 32 Pinheiro KV, Brusco I, Hausen BDS, Moresco RN, Rigo FK, Oliveira SM et al.. Efficacy of the World Health Organization analgesic ladder in the paclitaxel-induced pain syndrome in rats. Inflammopharmacology 2020. link 33 Lötsch J, Walter C, Zunftmeister M, Zinn S, Wolters M, Ferreiros N et al.. A data science approach to the selection of most informative readouts of the human intradermal capsaicin pain model to assess pregabalin effects. Basic & clinical pharmacology & toxicology 2020. link 34 Howard A, Brant JM. Pharmacologic Management of Cancer Pain. Seminars in oncology nursing 2019. link 35 Santos WBR, Melo MAO, Alves RS, de Brito RG, Rabelo TK, Prado LDS et al.. p-Cymene attenuates cancer pain via inhibitory pathways and modulation of calcium currents. Phytomedicine : international journal of phytotherapy and phytopharmacology 2019. link 36 Han FY, Whittaker A, Howdle SM, Naylor A, Shabir-Ahmed A, Smith MT. Sustained-Release Hydromorphone Microparticles Produced by Supercritical Fluid Polymer Encapsulation. Journal of pharmaceutical sciences 2019. link 37 Furgała A, Fijałkowski Ł, Nowaczyk A, Sałat R, Sałat K. Time-shifted co-administration of sub-analgesic doses of ambroxol and pregabalin attenuates oxaliplatin-induced cold allodynia in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018. link 38 Kawai H, Asaoka N, Miyake T, Nagayasu K, Nakagawa T, Shirakawa H et al.. Neurotropin inhibits neuronal activity through potentiation of sustained K. Journal of pharmacological sciences 2018. link 39 Gouveia DN, Pina LTS, Rabelo TK, da Rocha Santos WB, Quintans JSS, Guimaraes AG. Monoterpenes as Perspective to Chronic Pain Management: A Systematic Review. Current drug targets 2018. link 40 Wössner S, Weber K, Steinbeck AC, Oberhauser M, Feuerecker M. Pregabalin as adjunct in a multimodal pain therapy after traumatic foot amputation - A case report of a 4-year-old girl. Scandinavian journal of pain 2017. link 41 Anderson B, Lee S, Abd-Elsayed A. Emerging Drugs for the Treatment of Cancer Pain: A Review of Patent Literature in 2014. Recent patents on anti-cancer drug discovery 2017. link 42 Katz NP, Gajria KL, Shillington AC, Stephenson JJ, Harshaw Q. Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study. Postgraduate medicine 2017. link 43 Murad H, Ayuob N. Co-Administration of Pioglitazone Improves Fluoxetine's Antinociceptive, Neuroprotective, and Antidepressant Effects in Chronic Constriction Injury in Rats. Pain physician 2015. link 44 Yan PZ, Butler PM, Kurowski D, Perloff MD. Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. The Clinical journal of pain 2014. link 45 Rigo FK, Dalmolin GD, Trevisan G, Tonello R, Silva MA, Rossato MF et al.. Effect of ω-conotoxin MVIIA and Phα1β on paclitaxel-induced acute and chronic pain. Pharmacology, biochemistry, and behavior 2013. link 46 Kendall S, Holm NR, Højsted J, Frich L, Rotbøll Nielsen P, Jensen NH et al.. Chronic pain and the development of a symptom checklist: a pilot study. Acta anaesthesiologica Scandinavica 2013. link 47 Salvemini D, Doyle T, Kress M, Nicol G. Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain. Trends in pharmacological sciences 2013. link 48 Saw CL, Chew L, Goh C. Recent non-interventional advances in cancer pain among Singapore patients. Annals of the Academy of Medicine, Singapore 2012. link 49 Stanos S. Focused review of interdisciplinary pain rehabilitation programs for chronic pain management. Current pain and headache reports 2012. link 50 Udall M, Harnett J, Mardekian J. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. Journal of medical economics 2012. link 51 Mohamad AS, Akhtar MN, Khalivulla SI, Perimal EK, Khalid MH, Ong HM et al.. Possible participation of nitric oxide/cyclic guanosine monophosphate/protein kinase C/ATP-sensitive K(+) channels pathway in the systemic antinociception of flavokawin B. Basic & clinical pharmacology & toxicology 2011. link 52 Bennett MI, Flemming K, Closs SJ. Education in cancer pain management. Current opinion in supportive and palliative care 2011. link 53 Brant JM. Practical approaches to pharmacologic management of pain in older adults with cancer. Oncology nursing forum 2010. link 54 Kamen BA. Clinical aspects of pharmacogenetics of pain and co-morbidities of emotional distress. Asian Pacific journal of cancer prevention : APJCP 2010. link 55 Bender G, Florian JA, Bramwell S, Field MJ, Tan KK, Marshall S et al.. Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. The Journal of pharmacology and experimental therapeutics 2010. link 56 Jacobsen R, Samsanaviciene J, Liuabarskiene Z, Sciupokas A. Barriers to pain management among Lithuanian cancer patients. Pain practice : the official journal of World Institute of Pain 2010. link 57 Salvemini D, Neumann W. Targeting peroxynitrite driven nitroxidative stress with synzymes: A novel therapeutic approach in chronic pain management. Life sciences 2010. link 58 Tay W, Ho KY. The role of interventional therapies in cancer pain management. Annals of the Academy of Medicine, Singapore 2009. link 59 Balayssac D, Cayre A, Ling B, Maublant J, Penault-Llorca F, Eschalier A et al.. Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy. Neuroscience letters 2009. link 60 Montagnini ML, Zaleon CR. Pharmacological management of cancer pain. Journal of opioid management 2009. link 61 Panteli V, Patistea E. Assessing patients' satisfaction and intensity of pain as outcomes in the management of cancer-related pain. European journal of oncology nursing : the official journal of European Oncology Nursing Society 2007. link 62 Gramaglia L, Della Corte F, Fassiola A, Renghi A, Brustia P. Worsening of chronic pain: the treatment. Archives of gerontology and geriatrics 2007. link 63 Yokoyama T, Maeda Y, Audette KM, Sluka KA. Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. The journal of pain 2007. link 64 Waldron JB, Reid AR, Sawynok J. Amitriptyline produces multiple influences on the peripheral enhancement of nociception by P2X receptors. European journal of pharmacology 2004. link 65 Todorovic SM, Pathirathna S, Meyenburg A, Jevtovic-Todorovic V. Mechanical and thermal anti-nociception in rats after systemic administration of verapamil. Neuroscience letters 2004. link 66 Sorge J. The lesson from cancer pain. European journal of pain (London, England) 2000. link 67 Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yarnitsky D. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 1998. link00014-1) 68 Miller LJ, Kramer MA. Pain management with intravenous ketorolac. The Annals of pharmacotherapy 1993. link 69 Seltzer Z, Rappaport ZH, Zagzag D. A chronically implanted delivery system of drugs to a nerve-end neuroma: effects on a behavioural chronic pain model. Journal of neuroscience methods 1985. link90070-6)

Chronic painful polyneuropathy